Sandostatin LAR, Novartis

Sandostatin LAR (octreotide acetate)
Cancer
Novartis
Global Sales 2012:
$1.512 billion
U.S. Sales 2012: $649 million
Expiration Date: June 2014

Sandostatin LAR isn't among the most visible drugs in the Novartis ($NVS) portfolio. Lately, in fact, it's been playing second fiddle to Afinitor in press releases as Novartis works to develop the latter for broader treatment of endocrine tumors. Sandostatin, approved to treat acromegaly, a rare endocrine disorder, has been the base for Afinitor's add-on in a couple of recent trials. That's not unusual, of course, for a drug nearing the end of its exclusive hold on a market. Nor is it unusual for Novartis to trumpet the fact that a potential Sandostatin follow-up--Signifor, a.k.a. pasireotide--beat the older drug at controlling acromegaly symptoms in a recent trial.

What is unusual is that Sandostatin LAR figured prominently in recent whistleblower accusations of bribery in China. A former Novartis rep claims that her manager urged her to bribe doctors to increase use of the drug; the company is investigating the allegations. Another unusual feature of Sandostatin LAR's market position is that it already faces generic competition in most world markets, where patents expired in 2010. In the U.S., however, the drug doesn't lose exclusivity till June--and Novartis may soon be ready to follow up with Signifor. FDA-approved last December to treat Cushing's disease, another rare endocrine disorder, Signifor could be submitted for an acromegaly indication by the end of 2013. Its patent won't expire in the U.S. until 2026.

For more:
Novartis opens internal China probe after former rep demanded $800K
Novartis orphan drug Signifor gets another approval
Multibillion-dollar R&D strategy is paying off for Novartis

-- Tracy Staton (email | Twitter)

Sandostatin LAR, Novartis
Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.